SCHEMBL469262

SCHEMBL469262

COc1ccc(COC(=O)NC2(COc3cc4nccc(Oc5ccc(NC(=O)C6(C(=O)Nc7ccccc7)CC6)c(F)c5)c4cc3OC)CC2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKB Q96GD4 4/20 0.56
FLT1 P17948 3/20 0.56
MET P08581 10/20 0.55
AXL P30530 10/20 0.55
KDR P35968 7/20 0.55
MERTK Q12866 3/20 0.55
FLT3 P36888 3/20 0.55
KIT P10721 3/20 0.55
RET P07949 2/20 0.55
AURKA O14965 1/20 0.55
RIPK2 O43353 1/20 0.55
ABCB11 O95342 1/20 0.55
ABL1 P00519 1/20 0.55
EGFR P00533 1/20 0.55
ERBB2 P04626 1/20 0.55
NTRK1 P04629 1/20 0.55
LCK P06239 1/20 0.55
PGR P06401 1/20 0.55
LYN P07948 1/20 0.55
CHRM2 P08172 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL469355 0.93 AURKB (0.57) AURKBFLT1METAXLKDR
SCHEMBL454452 0.90 MET (0.64) AURKBFLT1METAXLKDR
SCHEMBL469346 0.86 MET (0.71) AURKBFLT1METAXLKDR
SCHEMBL469263 0.86 AURKB (0.58) AURKBFLT1METAXLKDR
SCHEMBL469257 0.85 MET (0.63) AURKBFLT1METAXLKDR
SCHEMBL469253 0.85 AURKB (0.58) AURKBFLT1METAXLKDR
SCHEMBL469255 0.85 MET (0.57) AURKBFLT1METAXLKDR
SCHEMBL469260 0.84 AURKB (0.57) AURKBFLT1METAXLKDR
SCHEMBL469258 0.83 AURKB (0.56) AURKBFLT1METAXLKDR
SCHEMBL469277 0.80 MET (0.67) AURKBFLT1METAXLKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2621904-B1 COMPOUNDS AS C-MET KINASE INHIBITORS ADVENCHEN LABORATORIES LLC (US) 2020-04-22 EP disclosed
US-8664244-B2 Compounds as c-Met kinase inhibitors Advenchen Pharmaceuticals, LLC (US) 2014-03-04 US disclosed
US-20120123126-A1 Compounds As c-Met Kinase Inhibitors CHEN GUOQING PAUL (US) 2012-05-17 US disclosed
WO-2012034055-A2 COMPOUNDS AS C-MET KINASE INHIBITORS ADVENCHEN LABORATORIES, LLC (US) 2012-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120123126-A1 Compounds As c-Met Kinase Inhibitors MET, MERTK, HGF AURKB 425/4885FLT1 30/4885MET 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.